Assembly Biosciences, Inc.

ASMB

US0453962070

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
13.72 ^USD	-6.03%		-12.28%	+39.41%

18/06	Assembly Biosciences, Inc. Doses First Participant in Phase 1B Clinical Trial Evaluating Next-Generation Capsid	CI
17/06	Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.	CI

ASSEMBLY BIOSCIENCES, INC. : Other Events (form 8-K)

January 04, 2020 at 03:10 am IST

top:Double

2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times

New Roman;font-size:10pt;">

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Latest news about Assembly Biosciences, Inc.

Assembly Biosciences, Inc. Doses First Participant in Phase 1B Clinical Trial Evaluating Next-Generation Capsid	18/06	CI
Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.	17/06	CI
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor Abi-6250 At the Easl Congress 2024	05/06	CI
Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing	19/01	MT
Assembly Biosciences, Inc. Provides Anticipated Development Milestones for 2024	04/01	CI
Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board	08/12	CI
Assembly Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Assembly Biosciences, Inc. Appoints Anuj Gaggar as Chief Medical Officer	08/11	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	17/23/17	MT
Sector Update: Health Care	17/23/17	MT
Assembly Biosciences Shares Soar Premarket on Gilead Pact	17/23/17	DJ
Transcript : Assembly Biosciences, Inc., Gilead Sciences, Inc. - Special Call	17/23/17
Gilead Sciences, Assembly Biosciences Working Together to Accelerate Development of New Antiviral Therapies	17/23/17	MT
Gilead Taking Stake in Assembly Bio Under Antiviral Collaboration	17/23/17	DJ
Gilead Sciences, Inc. and Assembly Biosciences, Inc. Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases	17/23/17	CI
Assembly Biosciences, Inc. announced that it expects to receive $15.165455 million in funding from Gilead Sciences, Inc.	15/23/15	CI
Assembly Biosciences Nominates Development Candidate Abi-6250, an Orally Bio Available HDV Entry Inhibitor	02/23/02	CI
Assembly Biosciences, Inc. to Present Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting	20/23/20	CI
Assembly Biosciences, Inc.(NasdaqGS:ASMB) dropped from S&P Global BMI Index	18/23/18	CI
Assembly Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Assembly Biosciences, Inc. Presents New Data Highlighting Herpes Simplex Virus Development Candidate Abi-5366 At the 47Th Annual International Herpesvirus Workshop	17/23/17	CI
Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05	CI
Assembly Biosciences Announces Additional Promising Data from Phase 1A Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate Abi-4334 and Provides Pipeline Update	18/23/18	CI

Chart Assembly Biosciences, Inc.

Duration

Period

More charts

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Companyâs pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-Î± (IFN-Î±) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Assembly Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.72 USD

Average target price

36 USD

Spread / Average Target

+162.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
ASSEMBLY BIOSCIENCES, INC.	+39.41%	9.26Cr
MERCK KGAA	+7.39%	7.24TCr
KYOWA KIRIN CO. LTD.	+15.93%	898.12Cr
YUHAN CORPORATION	+17.59%	427.96Cr
SK BIOPHARMACEUTICALS CO., LTD.	-22.81%	427.61Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+25.93%	401.45Cr
INDIVIOR PLC	+4.64%	216.43Cr
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+9.09%	194.66Cr
BETTA PHARMACEUTICALS CO., LTD.	-36.86%	190Cr
VELOXIS PHARMACEUTICALS A/S	-0.50%	164.41Cr

Specialty & Advanced Pharmaceuticals